Based on the Syros Pharmaceuticals Inc stock forecast from 3 analysts, the average analyst target price for Syros Pharmaceuticals Inc is USD 1.00 over the next 12 months. Syros Pharmaceuticals Inc’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Syros Pharmaceuticals Inc is Very Bearish, which is based on 0 positive signals and 9 negative signals. At the last closing, Syros Pharmaceuticals Inc’s stock price was USD 0.02. Syros Pharmaceuticals Inc’s stock price has changed by -2.80% over the past week, -70.33% over the past month and -99.56% over the last year.
No recent analyst target price found for Syros Pharmaceuticals Inc
No recent average analyst rating found for Syros Pharmaceuticals Inc
Company Overview Syros Pharmaceuticals Inc
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts. Read Less
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genom...Read More
Frequently Asked Questions About Syros Pharmaceuticals Inc (SYRS) Stock
Based on ratings from 3 analysts Syros Pharmaceuticals Inc's stock is Buy . Stock Target Advisor's fundamental analysis is Very Bearish. The stock has 1 buy, sell and 2 hold ratings.
Unfortunately we do not have enough data on SYRS's stock to indicate if its a good dividend stock.
Based on targets from 3 analysts, the average taret price for SYRS is USD 1.00 over the next 12 months. The maximum analyst target price is USD 1 while the minimum anlayst target price is USD 1.
SYRS stock's Price/Earning ratio is 7.38.
Our analysis grades SYRS stock's Price / Earning ratio at F. This means that SYRS stock's Price/Earning ratio is above 48% of the stocks in the Biotechnology sector in the OTC exchange.
Based on this SYRS may be fairly valued for its sector
The last closing price of SYRS's stock was USD 0.02.
The most recent market capitalization for SYRS is USD 0.48M.
Based on targets from 3 analysts, the average taret price for SYRS is projected at USD 1.00 over the next 12 months.
This means that SYRS's stock price may go up by +4,015.23% over the next 12 months.
We can't find any ETFs which contains Syros Pharmaceuticals Inc's stock.
As per our most recent records Syros Pharmaceuticals Inc has 68 Employees.
Syros Pharmaceuticals Inc's registered address is 35 CambridgePark Drive, Cambridge, MA, United States, 02140.
You can get more information about it from Syros Pharmaceuticals Inc's website at https://www.syros.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
There is nothing we particularly like
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Frequently Asked Questions About Syros Pharmaceuticals Inc (SYRS) Stock
Based on ratings from 3 analysts Syros Pharmaceuticals Inc's stock is Buy . Stock Target Advisor's fundamental analysis is Very Bearish. The stock has 1 buy, sell and 2 hold ratings.
Unfortunately we do not have enough data on SYRS's stock to indicate if its a good dividend stock.
Based on targets from 3 analysts, the average taret price for SYRS is USD 1.00 over the next 12 months. The maximum analyst target price is USD 1 while the minimum anlayst target price is USD 1.
SYRS stock's Price/Earning ratio is 7.38.
Our analysis grades SYRS stock's Price / Earning ratio at F. This means that SYRS stock's Price/Earning ratio is above 48% of the stocks in the Biotechnology sector in the OTC exchange.
Based on this SYRS may be fairly valued for its sector
The last closing price of SYRS's stock was USD 0.02.
The most recent market capitalization for SYRS is USD 0.48M.
Based on targets from 3 analysts, the average taret price for SYRS is projected at USD 1.00 over the next 12 months.
This means that SYRS's stock price may go up by +4,015.23% over the next 12 months.
We can't find any ETFs which contains Syros Pharmaceuticals Inc's stock.
As per our most recent records Syros Pharmaceuticals Inc has 68 Employees.
Syros Pharmaceuticals Inc's registered address is 35 CambridgePark Drive, Cambridge, MA, United States, 02140.
You can get more information about it from Syros Pharmaceuticals Inc's website at https://www.syros.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for SYRS !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
